Upstream Bio, Inc. - Asset Resilience Ratio
Upstream Bio, Inc. (UPB) has an Asset Resilience Ratio of 64.70% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Upstream Bio, Inc. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Upstream Bio, Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see UPB total asset value.
Liquid Assets Composition Over Time
This chart breaks down Upstream Bio, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read UPB current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $181.91 Million | 64.7% |
| Total Liquid Assets | $181.91 Million | 64.70% |
Asset Resilience Insights
- Very High Liquidity: Upstream Bio, Inc. maintains exceptional liquid asset reserves at 64.70% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Upstream Bio, Inc. Industry Peers by Asset Resilience Ratio
Compare Upstream Bio, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Upstream Bio, Inc. (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Upstream Bio, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 67.82% | $239.93 Million | $353.77 Million | +37.81pp |
| 2024-12-31 | 30.01% | $144.56 Million | $481.72 Million | -41.64pp |
| 2023-12-31 | 71.65% | $83.98 Million | $117.20 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $18.48 Million | -- |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.… Read more